Drugs / UniCAR02-T-pPSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04633148 | Nov 2020 → Mar 2024 | prostate cancer | AvenCell Europe GmbH | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UniCAR02-T-pPSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04633148 ↗ |
| Modality | Other / unclassified | “a combination of a cellular component (UniCAR02-T) with a recombinant antibody derivative (TMpPSMA)” NCT04633148 ↗ |
| Route | Intravenous | “Intravenous Infusion for 21 days” NCT04633148 ↗ |